Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, has announced positive topline results from its first Phase 1 clinical study of FB101. This investigational vaginal microbial immunotherapeutic has shown promising results in treating asymptomatic vaginal dysbiosis. The study was conducted in Europe and evaluated the change in vaginal microbiome after three conse..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms

AISA Pharma Announces Start of Phase 2b Profervia® Study for Raynaud's Phenomenon in Systemic Sclerosis (SSc)

Aisa Pharma has initiated the second part of its RECONNOITER Phase 2 study, which will evaluate Profervia®, an oral calcium-channel antagonist, in patients with systemic sclerosis and Raynaud's phenomenon. The double-blind, placebo-controlled, randomized, prospective crossover study is expected to last approximately 10 months. Aisa also presented positive safety and efficacy data from the Phase ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms